In addition, we examined the changes in Trop‐2 expression levels during the course of the disease, and between patient derived xenografts (PDX) [16] and their tumor of origin, in order to evaluate their suitability in preclinical studies targeting this biomarker. The gene discussed is TACSTD2; the disease is neoplasm.